Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study
This study aimed to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at...
Gespeichert in:
| Veröffentlicht in: | Daru 2015-02, Vol.23 (2), p.1-1 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1 |
|---|---|
| container_issue | 2 |
| container_start_page | 1 |
| container_title | Daru |
| container_volume | 23 |
| creator | Carnevale, Renata Cavalcanti Molino, Caroline de Godoi Rezende Costa Visacri, Marília Berlofa Mazzola, Priscila Gava Moriel, Patricia |
| description | This study aimed to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes. Intervention and control groups included 51 patients each. The authors observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm^sup 3^. None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures). |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1673384666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1673384666</sourcerecordid><originalsourceid>FETCH-LOGICAL-p616-45e350d87e652d9a7514b1950025e580e9a4222f7f4ff9777c29dc15621b9e683</originalsourceid><addsrcrecordid>eNpdkE9LAzEUxIMouFa_Q8CLl4X82SQbb7KoLRS8FK8lzb7QlHSzbrKFfntT9NTT8Jgfw5u5QRUjpK0Z4_QWVVRIUreUinv0kNKBEN42klVo38WUsRlMOCefcHR43JvpaCzM2VsTsDUT4HGKJ99Dj3PEy9V37QcHNpd7NNnDkNNricDmuPNpLIY_AbZxyFMMoUApz_35Ed05ExI8_esCbT7eN92yXn99rrq3dT1KKutGABekbxVIwXptlKDNjmpBCBMgWgLaNIwxp1zjnFZKWaZ7W8oxutMgW75AL3-x5eWfGVLeHn2yEIIZIM5pS6Xil-pSFvT5Cj3EeSpLXCjZKKGl4PwXAq5hvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1664759653</pqid></control><display><type>article</type><title>Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study</title><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Carnevale, Renata Cavalcanti ; Molino, Caroline de Godoi Rezende Costa ; Visacri, Marília Berlofa ; Mazzola, Priscila Gava ; Moriel, Patricia</creator><creatorcontrib>Carnevale, Renata Cavalcanti ; Molino, Caroline de Godoi Rezende Costa ; Visacri, Marília Berlofa ; Mazzola, Priscila Gava ; Moriel, Patricia</creatorcontrib><description>This study aimed to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes. Intervention and control groups included 51 patients each. The authors observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm^sup 3^. None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures).</description><identifier>ISSN: 1560-8115</identifier><identifier>EISSN: 2008-2231</identifier><language>eng</language><publisher>New York: Springer Nature B.V</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Drug therapy ; HIV ; Hospitals ; Human immunodeficiency virus ; Pharmaceuticals ; Pharmacists ; Studies</subject><ispartof>Daru, 2015-02, Vol.23 (2), p.1-1</ispartof><rights>Copyright Tehran University of Medical Sciences Publications Feb 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Carnevale, Renata Cavalcanti</creatorcontrib><creatorcontrib>Molino, Caroline de Godoi Rezende Costa</creatorcontrib><creatorcontrib>Visacri, Marília Berlofa</creatorcontrib><creatorcontrib>Mazzola, Priscila Gava</creatorcontrib><creatorcontrib>Moriel, Patricia</creatorcontrib><title>Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study</title><title>Daru</title><description>This study aimed to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes. Intervention and control groups included 51 patients each. The authors observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm^sup 3^. None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures).</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Drug therapy</subject><subject>HIV</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Pharmaceuticals</subject><subject>Pharmacists</subject><subject>Studies</subject><issn>1560-8115</issn><issn>2008-2231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkE9LAzEUxIMouFa_Q8CLl4X82SQbb7KoLRS8FK8lzb7QlHSzbrKFfntT9NTT8Jgfw5u5QRUjpK0Z4_QWVVRIUreUinv0kNKBEN42klVo38WUsRlMOCefcHR43JvpaCzM2VsTsDUT4HGKJ99Dj3PEy9V37QcHNpd7NNnDkNNricDmuPNpLIY_AbZxyFMMoUApz_35Ed05ExI8_esCbT7eN92yXn99rrq3dT1KKutGABekbxVIwXptlKDNjmpBCBMgWgLaNIwxp1zjnFZKWaZ7W8oxutMgW75AL3-x5eWfGVLeHn2yEIIZIM5pS6Xil-pSFvT5Cj3EeSpLXCjZKKGl4PwXAq5hvw</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Carnevale, Renata Cavalcanti</creator><creator>Molino, Caroline de Godoi Rezende Costa</creator><creator>Visacri, Marília Berlofa</creator><creator>Mazzola, Priscila Gava</creator><creator>Moriel, Patricia</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20150201</creationdate><title>Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study</title><author>Carnevale, Renata Cavalcanti ; Molino, Caroline de Godoi Rezende Costa ; Visacri, Marília Berlofa ; Mazzola, Priscila Gava ; Moriel, Patricia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p616-45e350d87e652d9a7514b1950025e580e9a4222f7f4ff9777c29dc15621b9e683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Drug therapy</topic><topic>HIV</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Pharmaceuticals</topic><topic>Pharmacists</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carnevale, Renata Cavalcanti</creatorcontrib><creatorcontrib>Molino, Caroline de Godoi Rezende Costa</creatorcontrib><creatorcontrib>Visacri, Marília Berlofa</creatorcontrib><creatorcontrib>Mazzola, Priscila Gava</creatorcontrib><creatorcontrib>Moriel, Patricia</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Daru</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carnevale, Renata Cavalcanti</au><au>Molino, Caroline de Godoi Rezende Costa</au><au>Visacri, Marília Berlofa</au><au>Mazzola, Priscila Gava</au><au>Moriel, Patricia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study</atitle><jtitle>Daru</jtitle><date>2015-02-01</date><risdate>2015</risdate><volume>23</volume><issue>2</issue><spage>1</spage><epage>1</epage><pages>1-1</pages><issn>1560-8115</issn><eissn>2008-2231</eissn><abstract>This study aimed to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes. Intervention and control groups included 51 patients each. The authors observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm^sup 3^. None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures).</abstract><cop>New York</cop><pub>Springer Nature B.V</pub><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1560-8115 |
| ispartof | Daru, 2015-02, Vol.23 (2), p.1-1 |
| issn | 1560-8115 2008-2231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1673384666 |
| source | SpringerNature Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Acquired immune deficiency syndrome AIDS Drug therapy HIV Hospitals Human immunodeficiency virus Pharmaceuticals Pharmacists Studies |
| title | Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A40%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20analysis%20of%20pharmaceutical%20care%20provided%20to%20HIV-infected%20patients:%20an%20ambispective%20controlled%20study&rft.jtitle=Daru&rft.au=Carnevale,%20Renata%20Cavalcanti&rft.date=2015-02-01&rft.volume=23&rft.issue=2&rft.spage=1&rft.epage=1&rft.pages=1-1&rft.issn=1560-8115&rft.eissn=2008-2231&rft_id=info:doi/&rft_dat=%3Cproquest%3E1673384666%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1664759653&rft_id=info:pmid/&rfr_iscdi=true |